Ventrix, a University of California San Diego spin-off company, has successfully conducted a first-in-human, FDA-approved Phase 1 clinical trial of an injectable hydrogel that aims to repair damage and restore cardiac function in heart failure patients who previously suffered a heart attack.
The trial is the first to test a hydrogel designed to repair cardiac tissue. It is also the first to test a hydrogel made from the natural scaffolding of cardiac muscle tissue, also known as extracellular matrix, or ECM. This is significant because ECM hydrogels have been shown in preclinical studies to potentially be effective for other conditions, such as poor blood circulation due to peripheral artery disease. The trial showed that the hydrogel, known as VentriGel, can be safely injected via catheter into patients who had suffered a heart attack in the past 2 to 36 months.
“Although the study was designed to evaluate safety and feasibility and not designed to show whether VentriGel effectively helps improve heart function, we observed some improvements in patients,” said Karen Christman, the paper’s senior author and a professor of bioengineering in the Jacobs School of Engineering and the Institute of Engineering in Medicine at UC San Diego. “For example, patients could walk longer distances. We also observed signs of improving heart function in patients who experienced a heart attack more than one year prior to treatment.”
Researchers from Ventrix, led by Christman, report their findings in the Sept. 11 issue of the Journal of the American College of Cardiology: Basic to Translational Science. Dr. Jay Traverse from the Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital was the lead clinical investigator.
There are an estimated 785,000 new heart attack cases in the United States each year, with no established treatment for repairing the resulting damage to cardiac tissue. After a heart attack, scar tissue develops, which diminishes muscle function and leads to heart failure. This is where VentriGel comes in. Once injected in damaged cardiac muscle, VentriGel forms a scaffold that acts as a reparative environment where healthy cells migrate, leading to increases in cardiac muscle, less scar tissue, and improvements in heart function.
VentriGel was invented by Christman and her team, then licensed from UC San Diego and developed by Ventrix, Inc, which was cofounded by CEO Adam Kinsey and Christman.
VentriGel is made from cardiac connective tissue taken from pigs, which is stripped of heart muscle cells through a cleansing process. It is then freeze-dried and milled into powder form, and then liquefied into a fluid that can be easily injected into heart muscle in a minimally invasive procedure that does not require surgery. Once it hits body temperature, the liquid turns into a semi-solid, porous gel.
The Phase 1 trial evaluated the gel in 15 patients who sustained moderate damage in the left ventricle chamber of the heart following a heart attack. Each patient received up to 18 injections of VentriGel into the damaged region via catheter. Researchers followed the patients for six months after treatment. All patients completed the full follow-up.
Twelve of the 15 patients were men. All 15 were experiencing mild to moderate heart failure following a heart attack. Half had suffered a heart attack within the past year.
Patients took a six-minute walking test as well as a heart function assessment and a heart health questionnaire before the injections. They retook the tests three and six months later. In addition, patients underwent an MRI at three and six months after the procedures.
Ventrix is now gearing up for a Phase 2 clinical trial that will expand on this successful first-in-human study. They are planning a larger, randomized trial that will evaluate how effectively VentriGel can improve cardiac function and quality of life for patients experiencing heart failure.
The Latest on: Heart repair
via Google News
The Latest on: Heart repair
- Transcatheter Aortic Valve Replacement Market will reach CAGR of 17.88% in 2023, Economic Impact in Cardiovascular Devices Sectoron November 29, 2019 at 11:50 am
... 360marketupdates.com/enquiry/request-sample/12363797 About transcatheter aortic valve replacement Transcatheter aortic valve replacement (TAVR) is a minimally invasive surgical procedure that ...
- Cardiologists undergo complex heart repair trainingon November 29, 2019 at 3:36 am
Cardiologists from different African countries have benefited from a free training in Periop imaging and treatment of complicated Congenital Heart Diseases (CHD) and Rheumatic Heart Diseases (RHD) in ...
- Cardiac Stem Cells can Repair Injured Hearton November 28, 2019 at 3:07 am
Cardiac stem cells can repair injured heart when injected directly into the heart tissue The healing process is mediated by macrophages through an acute innate immune response This results in ...
- How stem cells help repair heartson November 27, 2019 at 11:05 am
“The innate immune response acutely altered cellular activity around the injured area of the heart so that it healed with a more optimised scar and improved contractile properties,” says Molkentin.
- Stem-cell therapies use immune system to repair broken heartson November 27, 2019 at 10:16 am
Biologists have uncovered the mechanism by which stem-cell therapies improve heart function. Working in mice, a team of researchers found that the cells prompt an immune response that improves the ...
- Benefits of stem cell heart therapy may have nothing to do with stem cells, a study on mice suggestson November 27, 2019 at 10:08 am
The new work may provide a new direction for heart research, allowing researchers to examine whether harnessing the immune system could help repair the heart directly. Advances in understanding the ...
- Right-to-Repair Groups Don't Buy Apple’s Answers to Congresson November 27, 2019 at 3:01 am
He says there are instances when a repair to a solid-state drive or a Touch ID sensor on a Mac laptop will result in the replacement of the motherboard, which he likens to “prescribing a heart ...
- Chinese heart valve replacement maker Venus Medtech plans to raise up to US$381 million in Hong Kong IPOon November 26, 2019 at 7:11 am
Venus Medtech (Hangzhou), a Chinese maker of heart valve replacement devices, plans to raise as much as US$381 million in an initial public offering in Hong Kong next month, the latest sign that ...
- Life-saving heart repair a first for the Southern Hemisphereon November 26, 2019 at 6:43 am
... interventional cardiologist has pioneered an innovative heart procedure that is helping patients avoid heart failure and death. Macquarie University Hospital's Professor Martin Ng has successfully ...
- Filipino woman looks to SA to repair damaged hearton November 26, 2019 at 2:59 am
Johannesburg - A woman from the Phillipines has been given a new lease at life, thanks to South African doctors who performed a life-saving procedure to repair her damaged heart valve. Natascha ...
via Bing News